eCite Digital Repository

Agomelatine monotherapy for autism-A case report

Citation

Naguy, A and Pridmore, S and Jamali, MA and Hasan, AE and Alamiri, B, Agomelatine monotherapy for autism-A case report, Psychopharmacology Bulletin, 52, (4) pp. 100-103. ISSN 0048-5764 (2022) [Contribution to Refereed Journal]

Abstract

ASD is commonly associated with a host of challenging behaviours. Pharmacotherapy is indicated if psycho-social and educational interventions fail. Atypical antipsychotics have the strongest evidence-base so far, with both risperidone and aripiprazole are FDA-approved. Unfortunately, their use is fraught with metabolic and neuro-hormonal side effects. Here, authors report on a case of ASD/mild ID with behavioural dyscontrol that failed multiple psychotropic trials and ultimately responded favourably to agomelatine monotherapy. This was achieved with excellent tolerability. This might open new venues in such complicated cases.

Item Details

Item Type:Contribution to Refereed Journal
Research Division:Biomedical and Clinical Sciences
Research Group:Clinical sciences
Research Field:Psychiatry (incl. psychotherapy)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Treatment of human diseases and conditions
UTAS Author:Pridmore, S (Professor Saxby Pridmore)
ID Code:154222
Year Published:2022
Deposited By:Medicine
Deposited On:2022-11-14
Last Modified:2022-11-14
Downloads:0

Repository Staff Only: item control page